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Purpose: To assess the noninferiority, efﬁcacy, and safety of degarelix in achieving and maintaining
testosterone at castrate levels (0.5 ng/mL) in Korean patients (CS42) versus non-Asian patients with
prostate cancer (PCa).
Methods: A Phase III, open-label, multicenter, single-arm trial was conducted in Korean patients with
PCa. Degarelix was administered at a starting dose of 240 mg followed by monthly (28-day intervals)
maintenance doses of 80 mg (240/80 mg dose regimen) for 7 months. The results were compared with
non-Asian patients receiving degarelix 240/80 mg in the CS21 study.
Results: The estimated difference in the cumulative probabilities of testosterone 0.5 ng/mL from Day
28 to Day 196 between the trials was 2.3% (96.7% in CS42 vs. 99.0% in CS21). The lower limit of the 95%
conﬁdence interval was 5.5%, i.e., above the predeﬁned noninferiority limit of 10% and thus non-
inferiority was established. Decreases in serum testosterone, prostate-speciﬁc antigen, and luteinizing
hormone over time were similar in CS42 and CS21. There were no clinically signiﬁcant differences in
incidence of treatment-emergent adverse events (72% in CS42 vs. 70% in CS21) and changes in clinical
chemistry and hematology parameters between the two trials. The most common adverse event was
injection-site reaction.
Conclusions: Overall, degarelix was effective and well tolerated in Korean patients. Testosterone sup-
pression was noninferior to that in non-Asian patients and safety ﬁndings were as would be expected for
elderly men with PCa undergoing androgen deprivation therapy.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Androgen deprivation therapy (ADT) is ﬁrst-line treatment for
advanced/metastatic prostate cancer (PCa) and is also recom-
mended in combination with radiotherapy in the management of
intermediate and high-risk localized disease.1 For many years,
luteinizing hormone-releasing hormone (LHRH) agonists have
formed the mainstay of ADT. However, gonadotrophin-releasing
hormone (GnRH) antagonists offer a more recently developed
alternative ﬁrst-line ADT treatment option. The most extensivelyan Medical Center, University
, Songpa-gu, Seoul, 138-736,
ier B.V. on behalf of Prostate Intestudied and widely available antagonist worldwide is degarelix.
Unlike LHRH agonists, degarelix provides immediate GnRH recep-
tor inhibition resulting in rapid and profound testosterone
suppression.2
In the pivotal Phase III registration trial (CS21; NCT00295750),
conducted in Europe and North America, degarelix displayed
similar efﬁcacy to the LHRH agonist leuprolide in suppressing
testosterone over 1 year.3 However, degarelix reduced testosterone
and prostate-speciﬁc antigen (PSA) more rapidly with no initial
testosterone surge or subsequent microsurges, and no requirement
for ﬂare protectionwith antiandrogens. Studies show that response
to drug therapy can vary according to ethnicity.4,5 It is known that
racial differences within the androgen/androgen receptor pathway
not only exist but also could be causally related to clinically
observed differences in the biology of PCa among the ethnicity,rnational. This is an open access article under the CC BY-NC-ND license (http://
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drug evaluation should ideally include a population representative
of the target therapeutic population. In addition to studies in pre-
dominantly non-Asian populations, the efﬁcacy of degarelix has
also been studied in Japanese patients.7
The aim of the current trial (CS42; NCT01071915) was to
establish the efﬁcacy and tolerability of degarelix in Korean patients
with PCa and to establish noninferiority of degarelix in Korean
patients compared to non-Asian patients treated with the same
dose regimen in the pivotal phase III CS21 trial with regard to
achieving and maintaining castrate testosterone levels.
2. Methods
2.1. Study design
CS42 was an open-label, multicenter, single-arm trial in Korean
patients with PCa. Patients received subcutaneous injections of
degarelix 1-month depot at a starting dose of 240 mg (40 mg/mL)
followed by monthly (28-day intervals) maintenance doses of
80 mg (20 mg/mL; 240/80 mg dose regimen) for 7 months. The
results were to be bridged to those of the 240/80 mg arm of the
CS21 trial in non-Asian patients.3 Degarelix was supplied as a
freeze-dried powder for suspension in water.
The trial was conducted in accordance with the Declaration of
Helsinki as well as Good Clinical Practice Guidelines. The Institu-
tional Review Board at all participating institutions approved the
protocol. All patients provided written informed consent.
2.2. Patients
Korean men aged 18 years with histologically conﬁrmed
adenocarcinoma of the prostate (all stages), in whom androgen
ablation was indicated, except for neoadjuvant hormonal therapy,
were recruited. The population included patients with an
increasing PSA after having undergone prostatectomy or radio-
therapy with curative intent, i.e., those with biochemical failure or
metastatic disease (hormone-sensitive). Patients were required to
have a screening serum testosterone level >1.5 ng/mL and PSA
2 ng/mL, and an Eastern Cooperative Oncology Group score 2.
Previous or current hormonal management of PCawas not allowed,
except in patients who had undergone localized therapy of curative
intent in which neoadjuvant or adjuvant hormonal therapy for 6
months was accepted (discontinued >6 months before inclusion).
Patients considered candidates for curative therapy were excluded.
2.3. Assessment
The primary endpoint was the difference in cumulative proba-
bility of testosterone suppression to castrate levels (0.5 ng/mL)
from Day 28 to Day 196 between Korean patients and non-Asian
patients treated with the degarelix 240/80 mg dose regimen in
the CS21 trial. If noninferiority was established, the secondary
objective of showing that 7-month testosterone suppression
response rate was signiﬁcantly >90% in the full analysis set (FAS) in
Korean patients was tested; therefore this prioritized secondary
endpoint was the cumulative probability of testosterone 0.5 ng/
mL fromDay 28 to Day 196 in Korean patients. Secondary endpoints
also included the proportion of patients with testosterone 0.5 ng/
mL at Day 3, percentage change in PSA from baseline to Day 28,
cumulative probability of testosterone 0.5 ng/mL from Day 56 to
Day 196, serum levels of testosterone, luteinizing hormone (LH)
and PSA over time, and cumulative probability of no PSA failure (2
consecutive increases of 50%, and 5 ng/mL, compared to nadir).
Safety analysis comprised the frequency and severity of adverseevents (AEs) and clinically signiﬁcant changes in laboratory values,
electrocardiogram, physical examination, and vital signs. Blood
samples for analysis of testosterone, PSA, and LH were collected at
each trial visit. At dosing visits, blood sampling was performed pre-
dose and, where possible, at the same time of day, preferably in the
morning. A central laboratory (SCL, Seoul, Korea) measured serum
hormones (testosterone and LH) and PSA in accordance with Good
Laboratory Practice, using validated methods.
2.4. Determination of sample size
For sample size calculation, the 95% conﬁdence interval (CI) of
the testosterone suppression response rate for the CS21 240/80 mg
non-Asian reference population was 95.8e99.7%. Assuming a
response rate in Korean patients of 97% (lower than observed point-
estimate of 99% but still well within the CI) and a 15% annual drop-
out rate, 150 patients are required to have sufﬁcient power (90%)
in the FAS.
2.5. Statistical analysis
The primary analysis populationwas the FAS, deﬁned as patients
who received the study drug and in whom 1 efﬁcacy variable
(primary or secondary) was evaluated after administration.
Intention-to-treat (ITT) analysis comprised all patients who were
allocated to treatment, the per-protocol (PP) analysis was deﬁned
as FAS patients who did not violate speciﬁc predeﬁned criteria for
major protocol deviations which were in line with the CS21 trial,
and the safety analysis set comprised patients who received 1
degarelix dose.
The primary efﬁcacy endpoint (noninferiority assessment)
measuring the difference in cumulative probability of testosterone
0.5 ng/mL between Korean (CS42) and non-Asian (CS21) patients
receiving degarelix 240/80 mg, was estimated using the
KaplaneMeier (KM) method using testosterone measurements
from Day 28 to Day 196. The standard error of this estimate was
based on Greenwood's formula. The corresponding 95% two-sided
CI was constructed using the pooled standard errors of these esti-
mates. Noninferiority was established if the lower limit of this CI
was >10%. To determine effectiveness in Korean patients (priori-
tized secondary endpoint), testosterone suppression was consid-
ered statistically signiﬁcant if the lower limit of the two-sided 95%
CI was 90%. The two-sided 95% CI was derived in the same
manner as the primary endpoint.
The difference in proportion of patients with testosterone
0.5 ng/mL at Day 3 was tested using Fisher's Exact test (a ¼ 0.05,
two-sided). Median (interquartile range) percentage change from
baseline to Day 28 in PSA was calculated and groups tested using
the two-sample Wilcoxon test (a ¼ 0.05, two-sided). Cumulative
probability of testosterone 0.5 ng/mL from Day 56 to Day 196 was
estimated by the KM method. Cumulative probability of no PSA
failure was estimated using the KM method; groups were
compared using the log-rank test (a ¼ 0.05, two-sided).
3. Results
3.1. Patient disposition
The study was conducted between March 2010 and November
2011. Of 187 patients screened, 157 were allocated to treatment
(ITT). Of these, 156 (99%) received one or more degarelix dose
(safety population) and 155 (99%) had one or more efﬁcacy
assessment after dosing (FAS). Six FAS patients were excluded from
the PP analysis, which comprised 149 (95%) patients. The pro-
portions of patients completing CS42 (148/157; 94%) and 7 months
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similar. In CS42, patients (n ¼ 9) withdrew due to AEs (n ¼ 3),
withdrawal of informed consent (n ¼ 2), physician decision (n ¼ 2),
or other reasons (n ¼ 2). In the CS21 patient-cohort, nine patients
withdrew due to AEs, two were lost to follow-up, and seven dis-
continued for other reasons. Baseline age, testosterone, and PSA
were similar between CS42 and CS21; CS42 patients had higher
baseline LH (Table 1). CS42 had slightly more patients with locally
advanced PCa and slightly fewer with localized disease; in both
studies, >50% of patients had a Gleason score of 7e10.
Since the results for FAS and PP populations were similar, only
FAS data are reported.Fig. 1. KaplaneMeier plot (95% conﬁdence interval) of the cumulative probability of
testosterone 0.5 ng/mL from Day 28 to Day 196 in patients receiving degarelix 240/
80 mg in studies CS42 and CS21 (240/80 mg, non-Asian patients; full analysis set).3.2. Efﬁcacy
3.2.1. Cumulative probability of testosterone at castrate level
The estimated difference in the cumulative probability of
testosterone at castrate levels (0.5 ng/mL) from Day 28 to Day 196
between Korean patients in CS42 and non-Asian patients in CS21
was 2.3% for the FAS dataset. The lower limit of the 95% CI
was 5.5%, i.e., above the predeﬁned noninferiority limit of 10%
and noninferiority was thus established and, accordingly, bridging
between CS42 and CS21 was successful.
Fig. 1 shows KM estimates for cumulative probability of testos-
terone 0.5 ng/mL from Day 28 to Day 196 in CS42 and CS21 (FAS).
In CS42, one patient had a testosterone escape (>0.5 ng/mL) at Day
28 and two additional escapes occurred on Day 112 and Day 196.
KM estimates of the cumulative probability of testosterone0.5 ng/
mL were 96.7% (95% CI: 92.2e98.6%) in Korean patients (CS42)
versus 99.0% (95% CI: 95.9e99.7%) in non-Asian men in CS21 (log-
rank test, p ¼ 0.138; FAS dataset). Since the lower bound of the 95%
CI was above the 90% threshold, degarelix was shown to be effec-
tive in achieving and maintaining castrate testosterone levels in
Korean patients.3.2.2. Effect on testosterone over time
Decreases in testosterone over time were similar in CS42 and
CS21 (Fig. 2A). At Day 3, median testosterone was 0.26 ng/mL and
0.24 ng/mL in CS42 and CS21, respectively, and median percentage
decreases from baseline were 94.0% and 94.2%, respectively. The
proportion of patients with testosterone 0.5 ng/mL at Day 3 wasTable 1
Baseline patient characteristics.
Characteristic CS42 (n ¼ 155) CS21 (n ¼ 207)
Age (y) 74 (50e92) 72 (51e89)
Body mass index (kg/m2) 23.8 (16.6e42.2) 25.8 (17.3e42.2)
Testosterone (ng/mL) 4.03 (1.08e10.7) 4.1 (0.73e10.6)
Prostate-speciﬁc antigen, (ng/mL) 19.2 (1.59e100) 19.8 (1.7e3187)
Luteinizing hormone (IU/L) 7.9 (0.09e75.9) 5.85 (1.24e28)
Stage of disease at enrolment
Localized 43 (28) 68 (33)
Locally advanced 60 (39) 64 (31)
Metastatic 39 (25) 37 (18)
Not classiﬁable 13 (8) 37 (18)
Gleason score
2e4 e 20 (10)
5e6 24 (16) 68 (33)
7e10 130 (84) 118 (57)
Prior therapy
Radical prostatectomy 14 (9) 15 (7)
Radiotherapy 7 (5) 22 (11)
Neoadjuvant therapy 4 (3) 12 (6)
Watchful waiting 137 (88) 177 (86)
Data are presented as n (%) or median (range).
Fig. 2. Secondary endpoints. (a) Median (interquartile range) serum testosterone (ng/
mL) and (b) median (interquartile range) percentage change in serum prostate-speciﬁc
antigen (PSA; ng/mL), over time in patients receiving degarelix 240/80 mg in CS42 and
CS21 (240/80 mg, non-Asian patients; full analysis set).
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At Day 196, very similar decreases in testosterone were observed:
median serum testosterone had decreased by 98.4% and 98.1% in
CS42 and CS21, respectively (median testosterone at Day 196 was
0.070 ng/mL and 0.086 ng/mL in CS42 and CS21, respectively). In
addition, in CS42 and CS21, the KM estimates of the cumulative
probabilities of testosterone 0.5 ng/mL from Day 56 to Day 196
were 96.7% and 99.0%, respectively (log-rank test, p ¼ 0.140; FAS),
similar to the results from Day 28 onwards.
3.2.3. Effect on PSA over time
Decreases in serum PSA over timewere similar in CS42 and CS21
(Fig. 2B; FAS). The median percentage reductions from baseline to
Day 28 in PSA were 79.7% and 85.0% in CS42 and CS21, respectively
(p ¼ 0.030, Wilcoxon test; FAS). Corresponding decreases at Day 84
were 93.5% and 95.1%, respectively. At Day 196, PSA decreases were
96.2% and 97.0% and the absolute median PSA values were 0.67 ng/
mL and 0.60 ng/mL in CS42 and CS21, respectively (FAS).
The cumulative probability of no PSA failure from Day 28 to Day
196 was similar between CS42 and CS21, at 97.3% (95% CI:
93.1e99.0%) and 97.9% (95% CI: 94.5e99.2%), respectively; the
estimated difference between groups was not signiﬁcant (log rank
test, p ¼ 0.723; FAS). The probability of no PSA failure in CS42 and
CS21was lower in patients with baseline PSA>50 ng/mL (93.8% and
91% vs. 98e100% in lower baseline PSA categories) and in patients
with locally advanced (96.7% and 98.4%) and metastatic (94.6% and
91.2%) versus localized (100%) disease (FAS).
3.2.4. Effect on LH over time
Decreases in serum LH over time were similar in CS42 and CS21.
The median percentage decrease from baseline to Day 3 in serum
LH was 95.7% and 94.8% in CS42 and CS21, respectively. At Day 196,
median serum LH had fallen by 98.0% and 98.5%, respectively. The
absolute median values at Day 196 were 0.16 ng/mL and 0.09 ng/
mL, respectively.
3.3. Safety
Treatment-emergent AEs were reported by 72% of Korean pa-
tients in CS42 and 70% of non-Asian patients receiving degarelix
240/80 mg in CS21 (Table 2). The majority of AEs were mild or
moderate; severe AEs occurred in 7% of patients in CS42 and this
was comparable to the CS21 cohort (12%). Two (1%) patients died
during CS42 due to disease progression. There was no difference in
overall incidence of deaths between CS42 and CS21 (4 deaths;
cardiac arrest in 2 patients, gastric hemorrhage in 1 patient, and
bronchopneumonia in 1 patient). No deaths in either trial were
considered treatment-related.Table 2
Incidence of most frequent treatment-emergent adverse events.
Adverse event, n (%) CS42 (n ¼ 156) CS21 (n ¼ 207)
Any 113 (72) 144 (70)
Injection-site pain 34 (22) 55 (27)
Hyperhidrosis 14 (9) e
Injection-site erythema 13 (8) 35 (17)
Constipation 13 (8) 11 (5)
Upper respiratory tract infection 12 (8) 3 (1)
Nocturia 10 (6) 5 (2)
Hot ﬂusha 5 (3) 45 (22)
Injection site swelling 4 (3) 10 (5)
ALT increase 3 (2) 16 (8)
Hypertension 1 (<1) 12 (6)
ALT, alanine aminotransferase.
a Five (3%) patients also reported ﬂushing in CS42.The most common AE was injection-site reaction; the majority
were injection-site pain and injection-site erythema. Most
injection-site reactions were associated with the initial degarelix
dose and thereafter were much less frequent. No patient dis-
continued due to injection-site AEs and none were serious or se-
vere in intensity. Hot ﬂushes occurred in 22% of patients in CS21
versus 3% of patients in CS42 (3% of patients also reported ﬂush-
ing). Hyperhidrosis occurred in 9% of patients in CS42 versus none
in CS21.
In CS42, 18 (12%) patients experienced serious AEs (SAEs) of
which two (hyperglycemia and atrial ﬁbrillation) were considered
possibly related to degarelix. There were no major differences in
overall incidence or pattern of SAEs between CS42 and CS21. In
CS42, three (2%) patients had an AE that led to discontinuation; all
were considered unrelated to degarelix treatment. There were no
major differences in the overall incidence of AEs leading to
discontinuation between CS42 and CS21 (9 patients, 4%).
No clinically signiﬁcant differences were observed between the
two trials regarding changes in clinical chemistry and hematology
parameters from baseline to Day 196.
4. Discussion
Several data suggest that ethnical variations in the serum sex
hormone levels and androgen/androgen receptor pathway could
contribute to differences in the incidence and biology of PCa.6,8
Song et al9 found that a signiﬁcant proportion of Korean patients
with PCa exhibited poor differentiation, regardless of initial serum
PSA level or clinical stage at presentation, which resulted in a
greater rate of biochemical failure. Salonen et al10 found that a
signiﬁcant proportion of patients with aggressive and advanced
PCa do not respond adequately to ADT. Therefore, we assume that
the response to ADT experienced by Korean patients with PCa
might differ in other ethnicity.
These data establish the safety and efﬁcacy of degarelix in
Korean patients with PCa. Degarelix (240/80 mg regimen) was
noninferior with regard to achieving and maintaining testos-
terone at castrate levels (0.5 ng/mL) from Day 28 to Day 196
between Korean patients in CS42 and non-Asian patients in the
CS21 trial. Thus, the estimated difference in cumulative proba-
bilities of testosterone at  0.5 ng/mL from Day 28 to Day 196
between CS42 and CS21 met the predeﬁned noninferiority limit
of 10%. The cumulative probability of testosterone 0.5 ng/mL
from Day 28 to Day 196 in Korean patients was ~97%, similar to
that in CS21.
GnRH antagonists bind immediately and competitively to GnRH
receptors in the pituitary, providing rapid LH and testosterone
suppression.11 The rapid testosterone suppression with degarelix
has been noted in several trials,3,12,13 and was also observed in the
current cohort of Korean patients, with 97.4% achieving castration
by Day 3. The rapid testosterone suppression with degarelix con-
trasts with the delayed suppression observed with LHRH agonists
due to an initial testosterone surge, which may cause a transitory
exacerbation of clinical symptoms (ﬂare) in advanced disease.14,15
Also, as GnRH antagonists are not associated with testosterone
ﬂare, there is no need for antiandrogen coadministration.12,13
Moreover, LHRH agonist re-administration can raise testosterone
(acute-on-chronic response or microsurge).16 In CS21, testosterone
data on Day 252, Day 255, and Day 259 were analyzed to evaluate
testosterone microsurges. Eight patients (4%) receiving leuprolide
had microsurges, with testosterone breakthrough (>0.5 ng/mL)
occurring in four patients. There were no microsurges in any pa-
tient on degarelix.3 Berges and Bello17 suggested that an increase in
testosterone to >0.5 ng/mL might be clinically relevant, with po-
tential implications for treatment, and Morote et al18 found a
D. You et al. / Prostate International 3 (2015) 22e2626relationship between poor testosterone control and lower survival
free of androgen-independent progression. However, the clinical
signiﬁcance of testosterone microsurges and breakthroughs re-
mains to be fully determined.
Biochemical evidence of clinical improvement in Korean pa-
tients was demonstratedwith a rapid reduction in PSA (e.g., median
80% reduction from baseline by Day 28). The overall decline in PSA
was similar to that in non-Asian patients in CS21 and, furthermore,
in terms of PSA control, there was a similar probability of no PSA
failure in CS42 and CS21. These similarities in PSA response were
apparent despite a slightly higher percentage of high-risk patients
and/or patients with advanced PCa in CS42.
The tolerability of degarelix in Korean patients with PCa was
conﬁrmed, with comparable safety to that in non-Asian patients
receiving degarelix 240/80 mg in CS21. As expected, AEs associ-
ated with testosterone suppression, e.g., hot ﬂushes, were
observed, although these were tolerable. In CS42, while
injection-site reactions were frequent, these were mild or mod-
erate and of little clinical signiﬁcance. In addition, the incidence
of injection-site reactions in CS42 was lower than in CS21. In
CS21, although degarelix had a higher rate of injection-site re-
actions than leuprolide, this difference might reﬂect different
administration routes (subcutaneous degarelix vs. intramuscular
leuprolide) and injection volume.3 The types and incidence of
AEs in CS42 were not substantially different from previous clin-
ical studies of ADT. In addition, although the incidence of AEs was
slightly higher in CS42 than in CS21, there was no marked dif-
ference in the type and occurrence of SAEs and AEs leading to
discontinuation.
This present study may have limitations. The open study design
is an obvious limitation, especially in the interpretation of reported
AEs. However, in this single-arm study, degarelix was administered
subcutaneously at one dose and thus blinding was clearly not
possible. Another limitation is that the CS42 and CS21 trials were
performed independently. Even though two studies were per-
formed as the same design, it might be scientiﬁcally unreasonable
to compare independently performed studies.
In conclusion, the CS42 trial successfully conﬁrmed the previ-
ously demonstrated efﬁcacy of the 1-month degarelix depot by
meeting the predeﬁned criterion for noninferiority in testosterone
suppression rates between Korean and non-Asian patients. There
were rapid decreases in testosterone, PSA, and LH and the serum
proﬁles over time were comparable between CS42 and CS21.
Degarelix was well tolerated in Korean patients and in line with
what can be expected for elderly men with PCa undergoing ADT.
The results of an extension trial of CS42 (CS42A) will provide
longer-term safety and tolerability data for degarelix administered
up to 1 year in Korean patients with PCa.Conﬂicts of interest
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